What is Immunostics?
Immunostics specializes in the development, manufacturing, and sale of FDA-approved diagnostic kits and reagents for microbiological, serological, and immunological applications. Their core products are designed to detect fecal occult blood, a critical indicator for colorectal cancer and other gastro-intestinal disorders. The company holds multiple U.S. and international patents and trademarks, highlighting its commitment to intellectual property and innovation in the field of medical diagnostics.
How much funding has Immunostics raised?
Immunostics has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
What's next for Immunostics?
With the recent major strategic investment and its classification as large-scale late-stage funding, Immunostics is poised for significant growth and market penetration. This capital injection will likely be directed towards scaling manufacturing capabilities, expanding research and development for new diagnostic assays, and broadening its market reach. The company's focus on early detection of serious conditions like colorectal cancer positions it favorably within the healthcare sector, suggesting a trajectory towards becoming a leader in its specialized diagnostic niche.
See full Immunostics company page
